high mobility group box 1 pseudogene 44Genealiases: []
Q-omics provides the consensus-scored HMGB1P44 profile across patient tissues and cancer cell-line models. HMGB1P44 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, HMGB1P44 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, HMGB1P44 RNA expression shows 8,185 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, BRCA, and TGCT as cancer lineages where HMGB1P44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB1P44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB1P44 survival associations across molecular data types. HMGB1P44 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB1P44 RNA expression–survival associations across cancer types. High HMGB1P44 expression shows unfavorable associations in DLBC and KICH, but favorable associations in PAAD, HNSC, LUAD and ESCA. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify PAAD as the clearest survival context for HMGB1P44 RNA expression.
This table summarizes HMGB1P44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB1P44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB1P44 shows lower tumor expression in BRCA, BLCA and KIRP and higher tumor expression in HNSC. The BRCA box plot shows higher HMGB1P44 RNA expression in normal versus tumor tissue (log2 FC = −0.053, t-test p = .002).
This table shows molecular features associated with HMGB1P44 in patient tissues and cancer cell lines. In patient samples, HMGB1P44 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
